MGCD265 (GLESATINIB)

Background Information:

MGCD265 (Glesatinib) is an orally bioavailable, clinical stage
multitargeted tyrosine kinase inhibitor. It binds to and inhibits the
phosphorylation of several receptor tyrosine kinases (RTKs), including
the c-Met receptor (hepatocyte growth factor receptor); the Tek/Tie-2
receptor; vascular endothelial growth factor receptor (VEGFR) types 1,
2, and 3; and the macrophage-stimulating 1 receptor (MST1R or RON). It
is currently being evaluated clinically in patients with solid tumors
that have genetic alterations in MET or AXL genes, which have been
implicated as drivers of tumor growth and disease progression in NSCLC,
gastroesophageal cancer and other solid tumors.

APIM050196: MGCD265 (GLESATINIB)

CAS No.: 936694-12-1.
Molecular Formula: C31H27F2N5O3S2.
Molecular Weight: 619.7 (refer to Certificate of Analysis, batch-specific).
Purity: 99% chemical purity (HPLC at 214 and 254 nm).
QC: HPLC-MS, ¹HNMR and Quantitative Elemental Analysis.
Solubility: In DMSO.
Storage: 0 °C (short term), -20 °C (long term), Desiccated.